These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
244 related articles for article (PubMed ID: 33806229)
1. Intratumoral Virotherapy with Wild-Type Newcastle Disease Virus in Carcinoma Krebs-2 Cancer Model. Yurchenko KS; Glushchenko AV; Gulyaeva MA; Bi Y; Chen J; Shi W; Adamenko LS; Shestopalov AM Viruses; 2021 Mar; 13(4):. PubMed ID: 33806229 [TBL] [Abstract][Full Text] [Related]
2. Oncolytic effect of wild-type Newcastle disease virus isolates in cancer cell lines in vitro and in vivo on xenograft model. Yurchenko KS; Zhou P; Kovner AV; Zavjalov EL; Shestopalova LV; Shestopalov AM PLoS One; 2018; 13(4):e0195425. PubMed ID: 29621357 [TBL] [Abstract][Full Text] [Related]
3. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells. Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550 [TBL] [Abstract][Full Text] [Related]
4. Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting. Wu Q; Jin Y; Li S; Guo X; Sun W; Liu J; Li Q; Niu D; Zou Y; Du X; Li Y; Zhao T; Li Z; Li X; Ren G Int Immunopharmacol; 2024 Jul; 136():112305. PubMed ID: 38823178 [TBL] [Abstract][Full Text] [Related]
5. Combined therapy of oncolytic Newcastle disease virus and rhizomes extract of Rheum ribes enhances cancer virotherapy in vitro and in vivo. Al-Shammari AM; Jalill RDA; Hussein MF Mol Biol Rep; 2020 Mar; 47(3):1691-1702. PubMed ID: 31970625 [TBL] [Abstract][Full Text] [Related]
6. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Vigil A; Park MS; Martinez O; Chua MA; Xiao S; Cros JF; Martínez-Sobrido L; Woo SL; García-Sastre A Cancer Res; 2007 Sep; 67(17):8285-92. PubMed ID: 17804743 [TBL] [Abstract][Full Text] [Related]
7. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors. Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930 [TBL] [Abstract][Full Text] [Related]
8. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405 [TBL] [Abstract][Full Text] [Related]
9. Evaluation of the oncolytic potential of R Sharma KK; Kalyani IH; Mohapatra J; Patel SD; Patel DR; Vihol PD; Chatterjee A; Patel DR; Vyas B Arch Virol; 2017 Sep; 162(9):2705-2713. PubMed ID: 28578522 [TBL] [Abstract][Full Text] [Related]
10. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy. Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956 [TBL] [Abstract][Full Text] [Related]
11. Mesenchymal stem cells enhance the oncolytic effect of Newcastle disease virus in glioma cells and glioma stem cells via the secretion of TRAIL. Kazimirsky G; Jiang W; Slavin S; Ziv-Av A; Brodie C Stem Cell Res Ther; 2016 Oct; 7(1):149. PubMed ID: 27724977 [TBL] [Abstract][Full Text] [Related]
12. [Expressing foreign genes by Newcastle disease virus for cancer therapy]. Bai FL; Tian H; Yu QZ; Renl GP; Li DS Mol Biol (Mosk); 2015; 49(2):195-204. PubMed ID: 26065249 [TBL] [Abstract][Full Text] [Related]
13. The recombinant Newcastle disease virus Anhinga strain expressing human TRAIL exhibit antitumor effects on a glioma nude mice model. He J; An Y; Qi J; Cui L; Yang K; Liu M; Qu B; Yan S; Yin J; Jing X; Dong H; Yu Q; Li D; Wu Y J Med Virol; 2021 Jun; 93(6):3890-3898. PubMed ID: 32779745 [TBL] [Abstract][Full Text] [Related]
14. Analysis of three properties of Newcastle disease virus for fighting cancer: tumor-selective replication, antitumor cytotoxicity, and immunostimulation. Fournier P; Bian H; Szeberényi J; Schirrmacher V Methods Mol Biol; 2012; 797():177-204. PubMed ID: 21948477 [TBL] [Abstract][Full Text] [Related]
15. Newcastle disease virus: a promising agent for tumour immunotherapy. Zhao L; Liu H Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810 [TBL] [Abstract][Full Text] [Related]
16. Oncolytic Newcastle disease virus effects on immune response - a new issue in cancer treatment. Kooti W; Esmaeili HGG; Farzanehpour M; Dorostkar R; Jalali Kondori B; Bolandian M Klin Onkol; 2023; 36(2):124-129. PubMed ID: 37072246 [TBL] [Abstract][Full Text] [Related]
17. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines. Vijayakumar G; McCroskery S; Palese P J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938 [TBL] [Abstract][Full Text] [Related]
18. Newcastle disease virus as an oncolytic agent. Ravindra PV; Tiwari AK; Sharma B; Chauhan RS Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097 [TBL] [Abstract][Full Text] [Related]
19. Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment. Keshavarz M; Ebrahimzadeh MS; Miri SM; Dianat-Moghadam H; Ghorbanhosseini SS; Mohebbi SR; Keyvani H; Ghaemi A Virol J; 2020 May; 17(1):64. PubMed ID: 32370750 [TBL] [Abstract][Full Text] [Related]
20. [Progress in using Newcastle disease virus for tumor therapy: a review]. Wu Y; Hao J; Li D Sheng Wu Gong Cheng Xue Bao; 2010 Aug; 26(8):1031-6. PubMed ID: 21090105 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]